Saito T, Akita Y, Fujita H, Furukawa Y, Tsuchiya Y, Yasuda T, Yamamoto M, Kitagawa T, Nakagawa Y, Takehiro A
Acta Endocrinol (Copenh). 1986 Apr;111(4):507-15. doi: 10.1530/acta.0.1110507.
The activity of stimulatory guanine nucleotide regulatory protein (Ns) in the erythrocyte membrane was assayed by the reconstitution method using plasma membrane of cyc S49 mouse lymphoma cells in 18 patients with type I pseudohypoparathyroidism (PHP-I), 2 with pseudopseudohypoparathyroidism (PPHP) and 30 normal subjects, in parallel with other clinical parameters. The Ns activity as expressed by per cent of pooled standard (mean +/- SE) was 78.9 +/- 6.1 in PHP-I patients, which was significantly lower (P less than 0.01) than the value in normal subjects, 99.5 +/- 2.4. In PHP-I patients, the Ns activities (Y) were in significant correlation with three clinical parameters examined (X), i.e., with body height in standard deviation score from the mean of the normal population at the corresponding age, Y = 89.4 + 10.4X (r = 0.616, P less than 0.01); with urinary cAMP excretion in relation to creatinine [cAMP(nmol)/Cr(mg)], Y = 56.3 + 7.2X (r = 0.501, P less than 0.05); and with TSH levels in plasma (microU/ml), Y = 129 - 3X (r = 0.639, P less than 0.01). The Ns activities of PPHP were as low as 53.8 and 60.0. The decrease of Ns activity in the cell membrane may be implicated in the development of the clinical symptoms such as short stature, decrease in urinary excretion of cAMP and latent or manifest primary hypothyroidism in PHP-I and possibly in skeletal abnormality in PPHP.
采用重组法,以cyc S49小鼠淋巴瘤细胞质膜为材料,对18例I型假性甲状旁腺功能减退症(PHP-I)患者、2例假假性甲状旁腺功能减退症(PPHP)患者及30名正常受试者的红细胞膜中刺激性鸟嘌呤核苷酸调节蛋白(Ns)的活性进行了测定,并同时检测了其他临床参数。以混合标准品的百分比表示的Ns活性(均值±标准误),PHP-I患者为78.9±6.1,显著低于正常受试者的99.5±2.4(P<0.01)。在PHP-I患者中,Ns活性(Y)与所检测的三项临床参数(X)显著相关,即与相对于相应年龄正常人群均值的标准差身高,Y = 89.4 + 10.4X(r = 0.616,P<0.01);与尿中cAMP排泄量与肌酐的比值[cAMP(nmol)/Cr(mg)],Y = 56.3 + 7.2X(r = 0.501,P<0.05);以及与血浆促甲状腺激素水平(微单位/毫升),Y = 129 - 3X(r = 0.639,P<0.01)。PPHP患者的Ns活性分别低至53.8和60.0。细胞膜中Ns活性降低可能与PHP-I患者身材矮小、尿cAMP排泄减少以及潜在或明显的原发性甲状腺功能减退等临床症状的发生有关,也可能与PPHP患者的骨骼异常有关。